Mark Alan Goldberg - Net Worth and Insider Trading
Mark Alan Goldberg Net Worth
The estimated net worth of Mark Alan Goldberg is at least $3 Million dollars as of 2024-11-10. Mark Alan Goldberg is the Director of Immunogen Inc and owns about 53,800 shares of Immunogen Inc (IMGN) stock worth over $2 Million. Mark Alan Goldberg is the Director of Blueprint Medicines Corp and owns about 10,812 shares of Blueprint Medicines Corp (BPMC) stock worth over $1 Million. Mark Alan Goldberg is also the Director of GlycoMimetics Inc and owns about 11,497 shares of GlycoMimetics Inc (GLYC) stock worth over $4,741. Besides these, Mark Alan Goldberg also holds Aceragen Inc (ACGN) . Details can be seen in Mark Alan Goldberg's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Alan Goldberg has not made any transactions after 2022-03-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark Alan Goldberg
Mark Alan Goldberg Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Alan Goldberg owns 6 companies in total, including Blueprint Medicines Corp (BPMC) , Aceragen Inc (ACGN) , and Immunogen Inc (IMGN) among others .
Click here to see the complete history of Mark Alan Goldberg’s form 4 insider trades.
Insider Ownership Summary of Mark Alan Goldberg
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2022-03-03 | director |
| ACGN | Aceragen Inc | 2018-12-19 | director |
| IMGN | Immunogen Inc | 2019-09-30 | director |
 | | 2016-03-04 | director |
| | 2020-01-15 | director |
| | 2015-07-08 | director |
Mark Alan Goldberg Latest Holdings Summary
Mark Alan Goldberg currently owns a total of 4 stocks. Among these stocks, Mark Alan Goldberg owns 53,800 shares of Immunogen Inc (IMGN) as of November 6, 2018, with a value of $2 Million and a weighting of 60.54%. Mark Alan Goldberg owns 10,812 shares of Blueprint Medicines Corp (BPMC) as of March 3, 2022, with a value of $1 Million and a weighting of 39.28%. Mark Alan Goldberg also owns 11,497 shares of GlycoMimetics Inc (GLYC) as of March 4, 2016, with a value of $4,741 and a weighting of 0.17%. The other 1 stocks Aceragen Inc (ACGN) have a combined weighting of 0.01% among all his current holdings.
Latest Holdings of Mark Alan Goldberg
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IMGN | Immunogen Inc | 2018-11-06 | 53,800 | 31.23 | 1,680,174 |
| BPMC | Blueprint Medicines Corp | 2022-03-03 | 10,812 | 100.83 | 1,090,174 |
| GLYC | GlycoMimetics Inc | 2016-03-04 | 11,497 | 0.41 | 4,741 |
| ACGN | Aceragen Inc | 2018-12-19 | 588 | 0.38 | 223 |
Holding Weightings of Mark Alan Goldberg
Mark Alan Goldberg Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Alan Goldberg has made a total of 0 transactions in Immunogen Inc (IMGN) over the past 5 years. The most-recent trade in Immunogen Inc is the acquisition of 30,000 shares on November 6, 2018, which cost Mark Alan Goldberg around $172,800.
According to the SEC Form 4 filings, Mark Alan Goldberg has made a total of 7 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years, including 1 buys and 6 sells. The most-recent trade in Blueprint Medicines Corp is the acquisition of 5,000 shares on March 3, 2022, which cost Mark Alan Goldberg around $299,900.
According to the SEC Form 4 filings, Mark Alan Goldberg has made a total of 0 transactions in GlycoMimetics Inc (GLYC) over the past 5 years. The most-recent trade in GlycoMimetics Inc is the acquisition of 10,397 shares on March 4, 2016, which cost Mark Alan Goldberg around $49,594.
More details on Mark Alan Goldberg's insider transactions can be found in the Insider Trading History of Mark Alan Goldberg table.Insider Trading History of Mark Alan Goldberg
- 1
Mark Alan Goldberg Trading Performance
GuruFocus tracks the stock performance after each of Mark Alan Goldberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Alan Goldberg is 35.52%. GuruFocus also compares Mark Alan Goldberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Alan Goldberg within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Alan Goldberg's insider trading performs compared to the benchmark.
Performance of Mark Alan Goldberg
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.38 | | | | | |
| Relative Return to S&P 500(%) | 8.82 | | | | | |
Mark Alan Goldberg Ownership Network
Ownership Network List of Mark Alan Goldberg
Ownership Network Relation of Mark Alan Goldberg
Mark Alan Goldberg Owned Company Details
What does Blueprint Medicines Corp do?
Who are the key executives at Blueprint Medicines Corp?
Mark Alan Goldberg is the director of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include President & R and D Fouad Namouni , director & CEO & President Jeffrey W. Albers , and Principal FAO Michael Landsittel .
Blueprint Medicines Corp (BPMC) Insider Trades Summary
Over the past 18 months, Mark Alan Goldberg made no insider transaction in Blueprint Medicines Corp (BPMC). Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 165,808 shares made by Jeffrey W. Albers , a net sale of 38,146 shares made by Michael Landsittel , and a net sale of 14,415 shares made by Ariel Hurley .
In summary, during the past 3 months, insiders sold 27,744 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 27,744 shares. During the past 18 months, 464,866 shares of Blueprint Medicines Corp (BPMC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 464,866 shares.
Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Blueprint Medicines Corp Insider Transactions
Mark Alan Goldberg Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Alan Goldberg. You might contact Mark Alan Goldberg via mailing address: 128 Spring Street, Suite 520, Lexington Ma 02421.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
